Replies to post #33553 on Ayala Pharmaceuticals Inc (ADXS)

[Joche90]

The data from anal cancer pool is small. In order for advaxis to get the anal cancer approved, they will need to run another p3 which is costly. So they focus on getting the first product on to the market

[BarrellofHay]

I think their is a danger of FDA rejection for anal just based on the fact of n=11 is not enough. However, look at SRPT - this company gets FDA approval and sells their drug for muscular dystrophy and their is absolutely no statistical data that shows it works better than a placebo. Even the FDA admitted this and they sell it for 400k a year with medicare paying most.

So, it is a shame that 4,000 people a year with this deadly disease do not have access to something that appears to work awesome. Think about it, thousands of people are suffering and dying every year and their is as close to a cure as their can be right here!

[Simple Steve]

Exactly Bourbon. Great science. Promising results so far. And ADRO having similar products only reinforces ADXS products legitimacy. You do not see ADRO tanking like this. So why so hard to make deals with BP? Why aren't they knocking down the door? I've got to ask why is management (no matter who is the CEO) taking such a long long time to move things along? Isn't that a legitimate question us shareholders can ask?